Monday, February 05, 2024 5:33:09 PM
IF MF can finally finalize some type of deal
could bear fruit at some point.
that sector is still in its infancy
It now all rests on MF being able to finally execute
Nothing....all you got is a bunch of "ifs". Let me spell it out for you Z-E-R-O.
This has been going on nonstop for 4 years now. Where has it gotten the shareholders?
could bear fruit at some point.
that sector is still in its infancy
It now all rests on MF being able to finally execute
Nothing....all you got is a bunch of "ifs". Let me spell it out for you Z-E-R-O.
This has been going on nonstop for 4 years now. Where has it gotten the shareholders?
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
